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Nine human malignant gliomas (2 astrocytomas
grade III and 7 glioblastomas) were analyzed
using comparativegenomic hybridization (CGH).
In addition to the amplification ofthe EGFRgene
at 7p12 in 4 of9 cases, six new amplification sites
were mapped to 1q32, 4q12, 7q21.1, 7q21.2-3,
12p, and 22q12. Nonrandom chromosomal gains
and losses were identified with overrepresenta-
tion ofchromosome 7andunderrepresentation of
chromosome 10 as the mostfrequent events (1 of
2 astrocytomas, 7 of 7glioblastomas). Gain ofa
part or the whole chromosome 19 and losses of
chromosome bands 9pter-23 and 22q13 were de-
tected each in five cases. Loss of chromosome
band 1 7p13 andgain ofchromosome 20 were re-
vealed each in three cases. The validity oftheCGH
data was confirmed using interphase cytogenet-
ics with YAC clones, chromosome painting in tu-
mormetaphase spreads, andDNAfingerprinting.
A comparison of CGH data with the results of
chromosome banding analyses indicates that
metaphase spreads accessible in primary tumor
ceU cultures may not represent the clones pre-
dominant in the tumor tissue. (Am J Pathol
1994, 144:1203-1218)
Human malignant gliomas represent the most com-
mon primary malignant brain tumors.1' 2 Therapeutic
strategies that would considerably improve their
poor prognosis could not be developed. Chromo-
some banding and molecular genetic analyses of
these tumors have revealed a number of recurrent
genetic changes. The most frequent findings were
trisomy 7, monosomy 10 and 22, and partial dele-
tions of 9p and 17p and gonosomal losses. In addi-
tion, changes in the ploidy range, chromosomal re-
arrangements, involving in particular chromosomes
1 and 9, and double-minute chromosomes (DMs)
were observed.3 12 Amplification, rearrangements,
and overexpression of the epidermal growth factor
receptor (EGFR) gene were reported to occur in ap-
proximately 40% of malignant gliomas and consid-
ered to play a pivotal role in tumorigenesis.41325
Despite this progress, our knowledge of specific ge-
netic changes involved in the origin and develop-
ment of both benign and malignant human gliomas is
still insufficient.26
A new approach, termed comparative genomic
hybridization (CGH), has recently been intro-
duced.27 For this procedure, two-color fluorescence
in situ hybridization is applied to reference met-
aphase spreads with normal chromosome comple-
ments using a mixture of differentially labeled tumor
DNA and normal genomic DNA. After detection of
hybridized sequences with two fluorochromes, the
respective fluorescence intensities were measured
along the reference chromosomes. Fluorescence ra-
tio changes reflect copy number changes of chro-
mosomes or chromosomal segments within the tu-
mor and thus provide a survey of genetic imbalances
in tumor cells in a single in situ hybridization experi-
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ment. In addition to the identification of complete and
partial chromosome gains and losses this method
allows the mapping of DNA amplifications on refer-
ence metaphase chromosomes.27 32
Using CGH, we determined chromosome copy
number changes and DNA amplifications in nine hu-
man malignant gliomas. These data were compared
with the results of chromosome banding and DNA
fingerprinting analyses. In one complex case the
chromosomal origin of amplified DNA sequences
harbored in DMs was confirmed using fluorescence
in situ hybridization (FISH) on tumor metaphase
spreads, whereas interphase cytogenetics of tumor
nuclei using 16 chromosome band-specific yeast ar-
tificial chromosome (YAC) clones was applied to test
the reliability of the CGH data. Our study demon-
strates the potential of an integrated approach com-
bining conventional and molecular cytogenetic
methods to extend our knowledge of genetic
changes in gliomas and other solid tumors.
Materials and Methods
Clinical and Pathological Data
Clinical and histopathological data of malignant glio-
mas from three female and six male unrelated patients
are summarized in Table 1. Brain tumor material was
obtained during surgery. Seven patients suffered
from primary tumors and had not received chemo-
therapy or radiotherapy at the time of tumor resection.
Two tumor samples (cases no. 2 and 9) were obtained
from recurrent tumors. One patient (case no. 2) had
not received additional treatment, whereas the sec-
ond patient (case no. 9) underwent chemotherapy
and radiotherapy after the first surgery. The his-
topathological diagnosis of paraffin-embedded tis-
sue was performed according to the World Health
Organization classification.33
Chromosome Preparations
Metaphase chromosome spreads from primary cell
cultures of tumor samples were prepared as de-
scribed.12 Reference metaphase spreads for CGH
experiments were prepared from blood of healthy do-
nors (46,XX or 46,XY) using standard procedures.34
Slides were stored in 70% ethanol at 4 C until use.
DNA Preparations
Tumor DNA was extracted as described from frozen
tumor tissue samples.15 Isolation of reference
genomic DNA from peripheral blood lymphocytes of
a healthy male donor (46,XY) was performed accord-
ing to standard procedures.35
DNA Fingerprinting
DNA fingerprints from glioma DNA were generated
using the oligonucleotide probes (GT)8 and (GTG)5
and compared with the constitutional band pattern
obtained from the DNA of peripheral blood leukocytes
of each patient. A full-length cDNA from the EGFR
gene was used for Southern blot hybridization.15
Labeling of DNA Probes
Nick translation of DNA probes was performed fol-
lowing standard protocols.36 Tumor DNA was labeled
with biotin-1 x 6-dUTP (Boehringer Mannheim, Ger-
many) and reference genomic DNA was labeled with
digoxigenin-1 1-dUTP (Boehringer Mannheim). Alu
polymerase chain reaction (PCR) products of YAC
clones37.38 and chromosome-specific DNA libraries
were labeled with biotin-1 x 6-dUTP or digoxigenin-
1 1-dUTP.
Table 1. Clinical Data ofPatients and Histopatbological Data of Tumors
Primary/
Case Lab Histopathological Recurrent
No. No. Age/Sex Diagnosis Tumor Localization
1 233 49/f Anaplastic astrocytoma p r. frontal
grade IlIl
2 171 31//m Anaplastic astrocytoma r r. temporal
grade IlIl
3 94 72/m Glioblastoma p r. frontoparietal
4 256 59/m Glioblastoma p thalamic
5 83 61/f Glioblastoma p r. frontotemporal
6 143 59/f Glioblastoma p r. parietal
7 178 60/m Glioblastoma p 1. parietooccipital
8 237 69/m Glioblastoma p 1. parietal
9 253 12/m Glioblastoma r 1. frontoparietal
f, female; m, male; p, primary tumor; r, recurrent tumor; 1, left; r, right.
CGH
CGH was performed with tumor DNA as described29
with the following modifications: slides with reference
human metaphase spreads (46,XX or 46,XY) were de-
natured in 70% formamide, 2x standard saline citrate
(SSC) at 72 C for 2 minutes and dehydrated through
an ethanol series. To block highly repetitive se-
quences, an area of 18 x 18 mm2 was prehybridized
for 2 hours at 37 C with 50 pg of heat-denatured, un-
labeled Cotl DNA fraction (BRL/Life technologies,
Germany) in 50% formamide, 1 x SSC, and 10% dex-
tran sulfate. The coverslip was then removed and a
mixture of 100 ng of biotinylated tumor DNA and 100
ng of digoxigenin-labeled reference genomic DNA
added in 10 pl hybridization solution (50% form-
amide, 1 x SSC, 10% dextran sulfate). Hybridization
was performed for 3 days. Biotinylated DNA se-
quences were visualized by fluorescein isothiocya-
nate (FITC) conjugated avidin (Vector, Germany),
whereas digoxigenin-labeled sequences were de-
tected by indirect immunofluorescence using mouse
anti-digoxin (Sigma, Germany) and goat anti-mouse
Ig-tetramethylrhodamine isothiocyanate (TRITC) an-
tibodies (Sigma). Chromosome preparations were
counterstained with 4'-6-diamidino-2-phenylindole
dihydrochloride (DAPI) (Serva, Germany).
Chromosome Painting
Chromosomal in situ suppression (CISS) hybridiza-
tion of tumor metaphase spreads with whole
chromosome paint probes was conducted as de-
scribed.3639 Plasmid libraries from sorted chromo-
somes 4 and 7 were kindly provided by Dr. Joe Gray
(University of California, San Francisco).40
Interphase Cytogenetics
Single cell suspensions were prepared from fresh tu-
mor tissue as described,12 then directly fixed with
methanol/acetic acid and dropped on slides. These
uncultured tumor nuclei were used for two-color FISH
experiments with Alu PCR-amplified and -biotinylated
sequences from YAC clones.37 38 Sixteen YAC clones
were selected for the present experiments (Table 4).
For each clone the hybridization efficiency tested on
nuclei from phytohemagglutinin-stimulated lympho-
cyte cultures was .95%, ie, nuclei with two distinct
signals (data not shown). A minimum of 100 nuclei per
YAC clone was evaluated following the criteria de-
scribed by Hopman et al.41
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Fluorescence Microscopy
A Zeiss Axiophot microscope equipped with a 100 W
mercury lamp was used for epifluorescence micros-
copy. The filter sets for DAPI (LP 450-490, BP 365, FT
395), FITC (LP 515-565, BP 450-490, FT 510), and
TRITC (LP 590, BP 546, FT 580) were specifically
aligned to minimize image shifts. Microphotographs
were taken using Agfachrome 1000 RS color slide
films.
Digital Image Acquisition and Processing
Digital images from reference metaphase spreads
subjected to CGH were recorded for each fluoro-
chrome as described29 using a cooled charge
coupled device (CCD) camera (Photometrics, Tuc-
son, AZ) connected to an epifluorescence micro-
scope (Zeiss, Axiophot, Germany). For each case
evaluation of chromosomal imbalances and amplifi-
cation sites in gliomas was performed both by visual
inspection and calculation of fluorescence ratio pro-
files. For visual inspection digitized FITC and TRITC
images of 10 reference metaphase spreads and the
corresponding ratio images were analyzed.29 A five-
color lookup table was established according to the
results of CGH with test DNAs from cell populations
with specific monosomies and trisomies (S. du Manoir
et al, manuscript in preparation). Chromosomes were
identified using DAPI banding patterns. Photographs
were taken from the screen with Agfa RS 50 color slide
film. For fluorescence ratio profiles computer pro-
grams were developed on the basis of TCL-Image
(TNO Institute of Applied Physics, Delft, The Nether-
lands) running on a Macintosh Quadra 950. After de-
termination of the chromosomal axis, individual FITC/
TRITC profiles were calculated for each chromo-
some. Mean ratio profiles were determined from 10
metaphases. The central line in the profiles (Figures
2 and 5) represents the most frequently measured
fluorescence ratio for each reference metaphase
spread. The left and right vertical lines define thresh-
old values for underrepresentation and overrepresen-
tation of chromosome material (S. du Manoir et al,
manuscript in preparation).
Results
Chromosome Gains and Losses Detected
by CGH in Nine Malignant Gliomas
Clinical and histopathological data from the nine pa-
tients with malignant gliomas included in this study
are presented in Table 1. DNA extracted from frozen
1206 Schr6ck et al
AJPJune 1994, Vol. 144, No. 6
CGH Analysis of Malignant Gliomas 1207
AJPJune 1994, Vol. 144, No. 6
tumor samples was used for CGH analysis. For 10
reference metaphases ratio images were obtained
(see Materials and Methods). Figure 1, A shows a
typical example obtained from a recurrent glioblas-
toma (case no. 9). In a single ratio image, however, all
genetic imbalances may not be detected simulta-
neously (see below). Analysis of a series of reference
metaphase spreads is therefore indispensable for a
complete evaluation. CGH analysis of case no. 9 re-
vealed complex karyotypic changes including two
amplification sites (4q12 and 22q12, for further de-
tails see below), full or partial gains of chromosomes
1, 4, 5, 6, 7, 8, 17, 18, 19, 20, and 21, andfull orpartial
losses of chromosomes 2, 5, 9, 10, 11, 17, and 22.
Cytogenetic analysis of these complex changes was
not possible. Figure 2 demonstrates the average fluo-
rescence ratio profiles for each reference chromo-
some from 10 metaphases. The central vertical line
corresponds to the most frequently measured fluo-
rescence ratio and the right and left lines represent
the lower and upper limits of the normal range
(see Materials and Methods). Accordingly, a central
line ratio value for a given chromosome or chromo-
some segment reflects the presence of two copies
in pseudodiploid tumor cells, three copies in
pseudotriploid cells, four copies in pseudotetraploid
cells, and so forth.
In these average ratio profiles transitions between
balanced, underrepresented, and overrepresented
segments appeared less distinct than in the best re-
solved ratio images. This is due partly because these
transitions were also not distinct in individual ratio pro-
files obtained in some reference metaphases, and
because variations in the condensation of bands
along individual chromosomes were not taken into ac-
count when the length of chromosomes was normal-
ized for the calculation of the average ratio profiles.
In addition to the ratio profiles, the extent of partial
chromosome gains or losses was therefore identified
in optimally resolved ratio images of the respective
chromosomes. Compared with the ratio image (Fig-
ure 1, A, case no. 9) an additional small aberration
could be detected using the profile, ie, the exclusion
of bands 1 1q12-21 from the loss of 1 1q. On the other
hand, partial losses of 17p13 and 22q13 were clearly
seen in the best resolved ratio images but were not
apparent in the average ratio profiles of 10 chromo-
somes (see below). All other changes were detected
concordantly.
A survey of the copy number changes revealed in
all nine tumor samples is presented in Table 2 and
Figure 3. Because CGH would not detect a gain or
loss of a chromosome present in less than 50% of the
cells (our unpublished data), each chromosomal im-
balance reflects a genetic alteration present in most
cells of a malignant glioma in vivo. Imbalances of
chromosomes 7 and 10 were detected in all 7 glio-
blastomas and in 1 of 2 astrocytomas. Gain of the
whole chromosome 7 was found in cases no. 1, 3, 4,
5, 6, 8, and 9, whereas case no. 7 showed a partial
gain of 7pter-q31. Loss of the whole chromosome 10
was observed in cases no. 1, 3, 4, 5, 6, 7, and 8. Case
no. 9 showed a partial loss of 10q22-qter. A gain of
chromosome 19 was observed in four tumor samples
(cases no. 5, 6, 8, and 9), whereas a partial gain of
19q13.2-qter was detected in one sample (case no.
2). Three samples revealed a gain of chromosome 20
(cases no. 4, 8, and 9). Partial losses of 9p and 22q
were each detected in five samples (cases no. 1, 3,
6, 8, and 9 for 9p and cases no. 1, 3, 4, 7, and 9 for
22q). Losses restricted to the short arm of chromo-
some 17 were identified twice (cases no. 1 and 9),
whereas in a third sample (case no. 4) a complete loss
of chromosome 17 was noticed. Apparent consensus
Figure 1. A: Fluorescence ratio image ofa reference metaphase spread (46,XX) after CGH with glioblastoma DNA (case no. 9, FITC detection) and
reference DNA (TRITC detection) preparedfrom normal male lymphocytes (46,XY). A five-color lookup table (left upper corner) was chosen for the
visualization ofpixel by pixel FITCITRJTC ratios. The white color suggests a balanced state of chromosomes or chromosome segments in the tumor.
Green and blue colors represent moderately and highly increased ratio values indicative for the overrepresentation of the respective segments. Red
and yellow colors point to the underrepresentation of chromosome segments. For chromosome identification DAPI banding was applied (data not
shown). Blue coloring of chromosome bands 4q12 and 22q12 indicates two amplification sites (arrow heads). Arrows denote transition sites be-
tween an apparently balanced and underrepresented or overrepresented segments in several chromosomes. Identical transition sites are depicted
on homologue chromosomes. The pericentromeric and paracentromeric heterochromatic regions and the short arms of the acrocentric chromo-
somes were excludedfrom the calculation ofFITCMTRJTC ratios and visualized as gray shaded regions in this image (see Materials and Methods).
Note that colorization of specific chromosome segments was only considered significant if the same color was consistently obtained in a series of
ratio images and confirmed by average ratio profiles (compare Figure 2). Original magnification x 630. B: Tumor metaphase spread (case no. 9)
counterstained with DAPI (blue) after two-color chromosome painting with library DNA from flow soited chromosomes 4 (visualized with TRITC,
red) and 7(visualized with FITC, green). Note the presence offourpainted copies ofchromosome 7plus an additional chromosomefragment and
the presence ofchromosome 4 in approximately three copies. The redpainting of numerous DMs (some of them indicated by arrows) demonstrates
the presence of chromosome 4-derived sequences (compare Figure 6forfurther demonstration) in accordance with the detection of an amplifica-
tion on reference chromosomes 4 by CGH (compare Figures 1, A, 4, B, and 5). The microphotograph was taken by triple exposure ofa color slide
film. Original magnification x 630. C: Nucleifrom an uncultivated single cellpreparation of tumor tissue (case no. 9) after two-color CISS hybrid-
ization with two chromosome 1 -specific YAC clones (compare Table 4). Clone HTY 3222 maps to 1p36 ( TRITC detection, red signals). Clone HTY
3153 maps to 1q44 (FITC detection, green signals). Nuclei exhibit 3 to 5 red signals and 6 to 8 green signals. Note thatfocusing through the nuclei
was requiredfor accurate signal evaluation. Original magnification x 630.
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Figure 2. Average fluorescence ratio profiles
obtained from 10 reference metapbase spreads
subjected to CGH wvitb glioblastoma DNA (case
no. 9; compare Figuire 1, A). The central verti-
cal line represents the ratio value typicalfor a
balanced state of chromosome material, ie, two
copies for pseuidodiploid tumor cells and three I .Icopiesforpseudotriploid cells. The rght and left
linies represent thresholds indicative for chro-
mosomal gains (right line) and losses (left
line). Numerous gains and losses are indicated 6 7
in this chromosome copy numnber karyotype -
(compare Table 2). Note tu'o amplification sites
apparent at chromosome bands 4q12 and 2.722q12 (compare Figure 1, A). Due to the sup-
pression with Cot] DNA fraction, venr lou) FITC
and TRITC fluorescence intensities u'ere re-
corded at heterochromatic pericentromeric and
paracentromeric chromosome regions and on 13 14
the short arms of the acrocentrc chromosomes.
Th-ese gray shaded regions u'ere therefore ex-
cluded from evaluation. Black dots indicate the
mapping positions of YAC clones used for con-
firmation of the CGH data by> intebphase cyto- 1 20
genetics. At the right of each dot the average
signal tnumberfor 100 nucleifrom an unculti-
vated cell sample of case no. 9 is giwien (com-
pare Table 4).
regions for these chromosomes included 9pter-23,
17p13, and 22q13. Gains or losses of several other
chromosome regions were observed less frequently.
DNA Amplification Sites Mapped by CGH
Eleven DNA amplifications could be determined by
CGH and their origins mapped to seven different
chromosomal locations (Table 3). In all cases the am-
plification sites were seen as distinct signals on both
chromatids of the respective chromosomes in nearly
all reference metaphase spreads. Figure 4, A pre-
sents a reference metaphase spread obtained in a
CGH experiment with tumor DNA from case no. 5 in-
dicating three different amplification sites. Figure 4, B
shows examples of reference chromosomes 1, 4, 7,
12, and 22 with mapped amplification sites. The ad-
jacent images of the DAPI banded chromosomes
were used to determine the position of each site in a
series of these reference chromosomes. For each
case, average ratio profiles of chromosomes with
mapped amplification sites were determined in 10 ref-
erence metaphase spreads (Figure 5). In three of the
four cases with fluorescence peak values on chro-
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mosome 7 (cases no. 5, 6, and 8) these profiles
showed an elevated FITC/TRITC ratio along the entire
chromosome 7 indicating a gain of this chromosome
in the respective tumor samples. In one case (no. 7)
the ratio profile revealed a partial overrepresentation
of 7pter-q31. The amplification of the whole p arm of
chromosome 12 (case no. 2) is accompanied by loss
of genetic material of the q arm as indicated by a shift
of the high fluorescence ratio over 12p to values be-
low the lower threshold along 12q. In contrast, the
ratio profile for chromosome 1 (case no. 5) indicated
a balanced representation of its genetic material with
the exception of an amplification at 1q32. Similarly, a
balanced state is indicated for chromosome 4 (case
no. 3), which showed an amplification site mapped at
4q12. In case no. 9, which also showed an amplifi-
cation at 4q12, an elevated FITC/TRITC ratio along
the chromosome 4 indicated gains of chromosome
regions 4p and 4q26-qter in most cells of this tumor.
In four tumor samples (cases no. 5 to 8) a peak fluo-
rescence detected over band 7p12 suggested the
amplification of the EGFR gene. The EGFR gene
amplification was further demonstrated by DNA fin-
gerprinting (Table 3).
-
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Table 2. Results ofCGH and Cytogenetic Banding Analysis
Case Chromosomal Localization of Gains, Losses, and Amplification Sites (CGH results)
No Karyotype
XX, -(5)(q33-qter), + 7,-(9)(pter-23), + (9)(p1 1 -p13), + (9)(q 13-qter), - 1 0,- 15,-(16)(q22-qter), -(1 7)(p 13),
-(22)(ql 2-qter)
1
43-44,XX,add(2)(q35), +7,-8,der(9)1, +der(9)2,-10,add(l 1)(p1 5),der(1 6)t(2; 16)(q35;q34),i(1 7)(p1 0),
der(1 7; 1 9)(q 1 0;q10),-19,-22[5]/86-88,idemx2, +der(7), +der(8),-15[5]
XY,-(Xp), -(2)(q34-qter),-(5p),- 11,ampl.(12p),-(12q),-15, +(19)(q1 3.2-qter)
2
46,XY[84]/44-47,XY,+7,-22[cp4]
XY, +(3)(q28),ampl.(4)(ql 2), +7,-(9)(pter-23),-1 0,-(22)(ql 3)
3
46,XY,der(1)t(1; 12)(p36;q15),+7,-10,del(12)(q15),-14,add(15)(p1),+21 [22]/44-45,idem,-Y,dmin[8]
XY,-(4)(q27-qter),-6, +7,- 10,- 13,- 14,-17, +20,-22
4
46,XY[8]/45,X,-Y[23]
XX,ampl.(1)(q32.1), +7,ampl.(7)(pl 2),ampl.(7)(q21.2-3)-l1, + 19
5
44-46,XX[6]/47,XX, +7,dmin[2]
XX, +7,ampl.(7)(pl 2),-(9)(pter-21),-1 0, + 19
6
49,XX, +3, +7,add(9)(p21),del(9)(p21),-10, + 17, + 19[6]/43-45,XX, + 1, +3, +7,add(9)(p21),
del(9)(p21),-1 0, + 19[3]
XY,-(3)(ql2-23), +7(pter-q31),ampl.(7)(pl2),ampl.(7)(q21.1),-8,-10,-22
7
45,X,-Y[1 1]/46,X,-Y, +7[6]
XY, + 1 p, +(1)(q21-41),+7,ampl.(7)(p12),-(9)(pter-23),-10,(14)(q12-13),
+(19p)(high overrepr.),+19q,+20
8
85-90,XXYY,der(5)t(5;7)(pl O;ql 0);add(9)(p21 )x2,-l 0x2,add(13)(pl0)x2,-l 4x2,
-1 5x2,ins(15;?)(q22;?)x2,der(16)t(7; 16)(pl 3;q22)x2, + 19x2, +20x2,-21, +marl, +mar2[6]
XY, +(1 p), +(1 q)(high overrepr.),-(2)(q34-qter), +(4p),ampl.(4)(ql2), +(4)(q26-qter), +(5)(ql1-21),-(5)(q31 -qter),
+(6)(ql 2-q21), +7, +(8)(q24),-(9)(pter-23),-(9)(q21-22),-(10)(q22-qter),-(l1 p),-(11)(q22-23),-(17)(p13),
+(17)(q21-qter), +(18p)(high overrepr.), +(18q),+ 19,+20,+21,ampl.(22)(ql2),-(22)(ql3)
9
Polyploid with multiple structural aberrations and dmin
+, Gain of chromosomal material; -, loss of chromosomal material; ampl., amplification site, chromosomal localization of gene amplifica-
tion; high overrepr., high overrepresentation of this chromosomal region.
The karyotypes of two cases (no. 3 and 5) were already published by Thiel et al in 1992. In critical cases the origin of marker chromo-
somes was confirmed by chromosomal in situ suppression (CISS) hybridization with appropriate whole chromosome paint probes. This approach,
however, was restricted by the limited number of slides with metaphases from each case (G. Thiel and T. Lozanova, unpublished data).
Validity of CGH Data Tested by
Chromosome Painting and Interphase
Cytogenetics
To assess the validity of CGH to delineate multiple
genetic imbalances in solid tumors, case no. 9 was
paradigmatically chosen. The highest fluorescence
value using both image ratios and intensity profiles
was detected on 4q12. Therefore, this chromosomal
band was considered to harbor DNA sequences pre-
sumably amplified in the DMs of this tumor. This ex-
pectation was proven by painting of the DMs in tumor
metaphases using a painting probe for human chro-
mosome 4 (Figures 1, B and 6). To test the validity of
the copy number changes detected by CGH in this
tumor, a series of FISH experiments was performed to
interphase nuclei from uncultured tumor cells. Sixteen
YAC clones (Table 4, Figure 1, C) showing a hybrid-
ization efficiency of .95% on normal lymphocyte nu-
clei (see Materials and Methods) were selected to test
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Figure 3. Summary of genetic imbalances
detected by CGH in nine human malignant
gliomas. Losses are indicated by lines on the
left of each chromosome scheme, whereas
lines on the right represent gains. Chromo-
some bands to which amplification sites
could be mapped are indicated by squares.
The amplification of sequences present in an
entire 12p is indicated by a thick line.
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the presence of chromosomal sites in the tumor cells
for which average ratio values and/or visual inspec-
tion had indicated a balanced state, a loss, or a gain
(Figure 2). For case no. 9 mean numbers of nuclear
signals between 2.4 and 3.2 (with an average of 2.8
for all sites together) were counted after FISH with
probes for three chromosomal sites noted in an ap-
parently balanced state (Table 4, Figure 2). This result
indicates that this tumor contained predominantly
pseudotriploid cells. Probes for six chromosomal
sites for which losses were observed by CGH yielded
mean signal numbers between 1.8 and 2.0 (with an
average of 1.9 for all sites together). For six chromo-
somal sites with increased ratio values mean signal
numbers between 3.5 and 7.6 (with an average of 4.7)
were determined.
Apparent discrepancies between average fluores-
cence ratios and mean signal numbers were noted for
YAC clones HTY 3043 (9q34.3), HTY 3141 (17p13),
and HTY 3149 (22q13). All three YACs were derived
from a telomeric YAC library and define telomeric
chromosome regions. The difficulties to obtain reli-
able average fluorescence ratios at the very tip of a
chromosome will be discussed elsewhere (S. du
Manoir et al, manuscript in preparation). Notably, the
evaluation of FITC, TRITC, and ratio images from well
I
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Table 3. Chromosomal Localization ofAmplification sites,
Results ofDNA Fingerprinting, and Cytogenetic
Evaluation ofdmins
DNA
Fingerprinting: Cytogenetic
Case Amplification EGFR Analysis:
No. Site Amplification dmin
2 12p - -
3 4q12 - dmin
5 1q32 +
7p12 dmin
7q21.2-3 +
6 7p12 + -
7 7p12 + _
7q21.1
8 7p12 + -
9 4q12 - dmin
22q-12
The results of DNA fingerprinting of two cases (no. 3 and 5)
were already published (15).
resolved individual chromosomes 9, 17, and 22 were
in agreement with the results of the interphase cyto-
genetic analysis: enhanced FITC painting could be
noted at 9q34, whereas 17p13 and 22q13 showed
clearly less intense FITC painting.
Reference chromosomes for which the average ra-
tio profiles indicate that different parts were present in
different copy numbers in the tumor provide particu-
larly interesting opportunities to compare the results
of CGH and interphase cytogenetics. Ratio values for
chromosome 1 indicated a gain for both the short and
the long arm but the gain expected for the long arm
was clearly more pronounced (Figure 2). In concor-
dance with this ratio profile, two-color FISH with YAC
clones specific for the short arm (1p36, red fluores-
cence) and the long arm (1 q44, green fluorescence)
of chromosome 1 yielded four signals for 1 p36 and six
signals for 1q44 in 75 and 70%, respectively, of the
evaluated nuclei (Figures 1, C and 2, Table 4). CGH
ratio values and mean signal numbers showed a lin-
ear correlation (Figure 7). For 9 of 16 YAC clones the
signal numbers did not vary in 75% of the cells. This
led us to conclude that this tumor contained one main
clonal population. The more heterogeneous signal
numbers of the other seven YAC clones may corre-
spond to additive aberrations in this main clone or
other less abundant individual clones.
Results of Chromosome Banding
Analyses
In addition to the results of the CGH analyses the re-
sults of chromosome banding analyses of the nine
malignant gliomas are listed in Table 2. Notably, chro-
mosome banding and CGH analyses were performed
in different laboratories and the results were ex-
changed for comparison only after both analyses had
been completed independently. Numerous copy
number changes of chromosomes were concordantly
detected by both CGH and banding analyses. How-
ever, many striking discrepancies were also noticed
(see Discussion). To test for the presence of the Y
chromosome in tumors derived from males (Table 1,
6 cases) CGH was repeated, if necessary, on male
reference metaphases. In all these cases the Y chro-
mosome was specifically painted. In one case (no. 9)
the presence of the Y chromosome was also con-
firmed by interphase cytogenetics with the Y-specific
probe pYH 2.142 (data not shown).
Discussion
In this study numerous complete or partial chromo-
some gains and losses were identified by CGH in nine
malignant gliomas. In the following, we will first com-
pare the possibilities and limitations of CGH analysis
to reveal genetic changes in these or other solid tu-
mors with the possibilities and limitations of cytoge-
netic and other molecular genetic approaches. Sec-
ond, we will discuss the implications of this study for
the biology of malignant gliomas.
Comparison of CGH with other
Approaches to Study Genetic Imbalances
in Malignant Gliomas
Not all complete and partial chromosomal gains and
losses detected by CGH could be identified by chro-
mosome banding analysis. Conversely, some chro-
mosomal aberrations found by banding analysis were
not detected by CGH (Table 2). Several reasons may
account for these discrepancies. CGH defines gains
and losses that are present in the tumor sample in vivo
but will only detect chromosome imbalances present
in the majority of the cells (>50%, unpublished ob-
servations) from which DNA was prepared. In con-
trast, mitotic cells that are analyzed in a tumor cell
culture may represent tumor subclones and normal
cells selected by growth advantages in vitro and may
contain additional chromosome aberrations that oc-
curred during in vitro culture.
Chromosome painting and interphase cytogenet-
ics confirmed the results of the CGH analyses. Inter-
phase cytogenetics39,41'43 was particularly useful to
evaluate samples of uncultured tumor cells for the
presence of chromosomal gains and losses indicated
by CGH. It should be noted that CGH does not pro-
vide information on the ploidy level of a given tumor.
Such information can be obtained by interphase cy-
togenetics with DNA probes that map to chromosome
sites showing fluorescence ratio values at the central
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Figure 4. A: Microphotograph ofa reference metaphase spread subjected to CGH with glioblastoma DNA of case no. 5 shows the FITCfluorescence
of hybridized tumor DNA sequences. Three amplification sites at chromosome bands lq32, 7p12, and 7q21.2-3 are indicated by arrows. Mapping
positions were identified by companison with DAPI banded chromosomes (compare B). B: Mapping of seven different amplification sites to refer-
ence metaphase chromosomes by CGH. Gray scale pictures of the chromosomces uere taken with a CCD camera anld pseudocolored uising image
processing (bluie, DAPI counterstaining; green, hybndization signzals of FIT,C-detected tutmor DNA). Intensely flutorescence sites were recorded on
chromosomne banids 1q132 (case no. 5), 4q12 (case no. 9), 7p12 and 7q21.2-3 (case nio. 5), 7p12 ancd 7q21.1 (case nio. 7), 12p (case no. 2), anid
22q12 (case no. 9). TRJTC fluorescence image-s of these chromosomes reflectinig the hYbridization of reference DNA sequenccs showed a homog-
enous staining exceptfor the ueakly stained heterochromnatic regions (data not shown). Average fluorescence ratio profilecs indicating complete or
partial gainis and losses of these chromosomes are demonstrated in Figulre 5. Orginial nagnyfication x 630.
line (see Results) or by measurements of the DNA
content of individual tumor nuclei using flow cytom-
etry or image analysis microscopy (not performed in
this study).
Molecular genetic approaches, for example the
search for a loss of heterozygosity (LOH) in certain
regions of a tumor genome, are mostly performed in
a highly focused manner. If screening of a whole tu-
mor genome is attempted in this way, large numbers
of hybridization or PCR experiments have to be con-
ducted requiring a set of informative probes or oli-
gonucleotide primers spanning the entire genome. In
contrast to CGH, however, LOH studies provide the
advantage to distinguish between alleles. A loss of a
particular chromosome region followed by reduplica-
tion of the remaining chromosome can be identified
by LOH but not by CGH. Both CGH and studies of
LOH have in common that they provide information for
genetic changes present in the large majority of cells
but do not allow studies of clonal heterogeneity. This
limitation may be overcome in the near future. CGH
analysis after degenerate oligonucleotide primed
(DOP)-PCR31 allows to study samples comprising
only a few tumor cells. Recent improvements of uni-
versal DNA amplification suggest even the possibility
that CGH may become possible on a single cell ba-
SiS.44 We anticipate that the isolation of a few nuclei
or even a single nucleus from appropriately frozen,
fixed, and paraffin-embedded tissue sections will
make it possible to study the genetic basis of the his-
topathologically characterized cellular heterogeneity
of malignant gliomas and other solid tumors.
In our study DMs were observed in 3 of 9 malignant
gliomas by cytogenetic analysis. This result is in
agreement with other investigations where DMs were
observed in approximately 30% of malignant glio-
mas. 12 However, using CGH 11 DNA amplifications
on 7 different chromosomal locations were detected
in 7 of 9 cases. These findings support the assump-
tion that karyotyping may underestimate the fre-
quency of gene amplification.28
In conclusion, each of the cytogenetic and molecu-
lar cytogenetic approaches used in this study, ie,
chromosome banding, CGH, chromosome painting,
and interphase cytogenetics, revealed both informa-
tion confirming the results of the other approaches
and unique information. Although CGH is a superior
approach to establish copy number karyotypes
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avoiding the artifacts of tumor cell cultures, chromo-
some banding, chromosome painting, and FISH with
band-specific DNA clones provide possibilities to
study the actual genetic composition of marker chro-
mosomes and the distribution of amplified sequences
in DMs and/or marker chromosomes of individual tu-
mor cells. Reciprocal rearrangements can be identi-
fied by these other approaches but not by CGH. A
comprehensive evaluation of cytogenetic changes in
solid tumors should therefore be based on an inte-
grated approach. The application of CGH as a routine
diagnostic tool should be strongly faciliated in the fu-
ture by the development of automated CGH tests.29
Implications of CGH Data for the Study of
Genetic Events in the Development of
Malignant Gliomas
Six new amplification sites were detected by CGH in
5 of 9 malignant gliomas and localized to chromo-
some bands 1 q32,4q12 (2x), 7q21.1, 7q21.2-3, 12p,
and 22q12. The following potential candidate genes
were reported to map to the amplified genomic re-
gions45 and might play a role in the regulation of
growth control in glial tissue: CD45 (a leukocyte com-
mon antigen), polymeric immunoglobulin receptor,
CD46 complement membrane cofactor protein, and
transforming growth factor beta 2 map to 1q31-41.
The involvement of cell surface factors like CD45 or
CD46 in glioma development may be considered be-
cause CD44, the human lymphocyte homing recep-
tor, was found to be strongly expressed in high grade
gliomas but weakly in normal brain cells.46 The am-
plification of 4q12 was detected in two unrelated
cases. Among others the genes for alpha polypeptide
of the platelet-derived growth factor receptor (PDG-
FRA) and alpha fetoprotein were mapped to this chro-
mosomal region. Overexpression and an aberrant
transcript of PDGFRA was detected in glioblasto-
mas.21,47 On 12p potential genes that might be in-
volved in tumorigenesis of gliomas include the genes
for CD4 and CD9, fibroblast growth factor 6, tumor
necrosis factor receptor 1, and the v-Ki-ras2 onco-
gene homologue. The platelet-derived growth factor
I
m
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A B C
Figure 6. A: DAPI stained tumor metaphase spread (case no. 9) shows numerous DMs (some of them indicated by arrows). B: The same met-
aphase spread after CISS hybridization with library DNA from flow sorted chromosomes 4 detected with TRtTC. In addition to three painted chro-
mosomes the specific painting ofDMs is noted indicating the presence of chromosome 4-derived sequences. C: Simultaneous painting of the same
metaphase spread with library DNA from flow sorted chromosome 7 demonstrates the painting offive chromosomes but none of the DMs (compare
Figure 1, B). Original magnification X630.
Table 4. Comparison of the Results ofCGH Analysis of a Pseudotniploid Glioblastoma with Interphase Cytogenetics Using
Band-Specific YAC Clones (case no. 9)
CGH Results, Numbers of Signals Per Cell (%)
Gains, and Interphase FISH Locali- Mean of
Losses YAC Clone zation 100 cells 0 1 2 3 4 5 6 7 8 9
Balanced state HTY 3113 3p21 2,4 2 5 45 42 6 0 0 0 0 0
Balanced state YAC7 13q14 2,7 2 7 36 49 5 1 0 0 0 0
Balanced state HTY 3010 15q21 3,2 3 2 10 51 30 4 0 0 0 0
Balanced state HTY 3043 9q34.3 3,8 1 1 8 8 77 4 1 0 0 0
-(2)(q34-qter) HTY 3118 2q36-37 1,8 3 18 74 4 1 0 0 0 0 0
-(10)(q22-qter) HTY 3179 10q24-25 1,8 1 15 81 3 0 0 0 0 0 0
-(5)(q31-qter) HTY 3213 5q31 1,9 2 16 74 8 0 0 0 0 0 0
-(9)(q21-22) HTY 3143 9q21 1,9 2 7 90 1 0 0 0 0 0 0
-(22)(q13) HTY 3149 22q13 1,9 3 11 77 8 1 0 0 0 0 0
-(17)(p13) HTY 3141 17p13 2,0 1 8 86 4 1 0 0 0 0 0
+(5)(q 1-21) HTY 3026 5q13-14 3,5 1 1 16 17 62 3 0 0 0 0
+21 HY129 21q21 3,7 2 2 4 14 73 5 1 0 0 0
+(1p) HTY 3222 1p36 3,8 2 0 8 8 75 7 0 0 0 0
+7 HTY 3172 7q36 4,0 3 2 7 10 41 32 3 2 0 0
+(1q) HTY 3153 1q44 5,7 0 0 2 2 7 11 70 8 0 0
+18 HTY 3045 18q23 7,6 0 0 2 2 0 0 7 8 70 1 1
YAC clone YAC7 was kindly provided by Dr. Eric Green and YAC clone HY 129 was a gift from Drs M.-C. Poitier and M. Goedert. The other
14 YAC clones were mapped in our laboratory (A. Jauch, H. Donis-Keller, T. Cremer, unpublished data).
beta polypeptide (PDGFB) gene provides a candi-
date gene on 22q. The expression of PDGFB is higher
in gliomas than in peritumoral and normal nervous
tissue48 and both PDGFA and PDGFB are higher ex-
pressed in glioblastomas than astrocytomas.49 Fur-
ther cytogenetic, molecular genetic, and biochemical
studies are necessary to identify the amplified DNA
sequences and to understand their influence on tu-
mor biology.
Trisomy of chromosome 7 is the most frequent
chromosomal aberration in astrocytomas ranging
from 15% in benign low grade astrocytomas to
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a marker of malignancy in human gliomas. The search
for possible tumor suppressor genes on this chromo-
some has been actively pursued with studies for loss
of heterozygosity.2 11'52-54 Cytogenetic results indi-
cated a loss of a whole chromosome 10 in approxi-
mately 30 to 60% of malignant gliomas.7'612 In our
collection karyotyping revealed monosomy 10 for 4 of
8 analyzable cases. Using CGH, however, this spe-
cific aberration was noted in 8 of 9 cases. All seven
glioblastomas revealed losses of chromosome 10
with a restriction to 10q21-qter in one case.
Chromosomes 9, 17, 19, and 22 are preferred tar-
gets for chromosomal aberrations in gliomas but less
frequently involved than chromosomes 7 and 10. Cy-
togenetic and molecular analyses revealed structural
aberrations and LOH of chromosomes 9, 17, and
22. Using CGH, partial losses of 9p and 22q
i,0 1,5 2,0 have been observed in 5 of 9 cases each with con-
DENT RATIO sensus regions mapped to 9pter-23 and 22q13. The
escence ratios calculated for 16 latter region is also frequently involved in meningio-
metaphase spreads subjected to mas.60.61 The partial loss on chromosome 17p was
no. 9). Ordinate: average signal obtained in 3 of 9 cases with the consensus region of
sites evaluated by interphase cyto-
s of this case with 16 human YAC 17p13. Mutations and deletions of the p53 gene were). A linear correlation with a re- revealed in LOH studies of several types of tumors
erved between the average signal
'nce ratio values, including gliomas.53'55 However, restriction fragment
length polymorphism analyses of 40 gliomas sug-
t high grade astrocyto- gested that a tumor suppressor gene other than p53
ysis observed an overrep- is located on 17p13 and involved in progression to
= 7 in 1 of 2 anaplastic as- malignancy.56 This is supported by studies of malig-
d in all glioblastomas (7 nant astrocytomas62 and pediatric primitive neuroec-
)nstrate that overrepresen- todermal tumors.63 Contradictory findings have been
present in the majority of reported on the involvement of chromosome 19. Tri-
dependently performed G somy 19 was observed by cytogenetic analysis,
a clonal trisomy 7 in 5 of whereas loss of constitutional heterozygosity and par-
causative role of chromo- tial deletions were reported in LOH studies.' 164 This
In in the pathogenesis of CGH analysis revealed a gain of chromosome 19 in
d, because trisomy 7 has 4 of 9 cases and a partial gain of 19q13.2-qter in 1
epithelial tissues.51 How- case. However, we do not know the allelic status of the
lification sites detected by cases with the extra copies of chromosome 19, and
involvement of this chro- partial deletions detected by LOH may reflect sub-
votal role of chromosome 7 microscopic deletions. Combined CGH and LOH
of human gliomas. These studies are necessary to shed light on this problem.
EGFR gene, which was The loss of the Y chromosome is a common ob-
cases in our study (see servation of cytogenetic analyses in gliomas.7812
additional amplifications However, it was discussed also as a culture artifact,
,hromosome at 7q21 .1 and because interphase cytogenetics revealed the loss of
ations of normal brain tis- the Y chromosome less frequently.65'66 In six malig-
of low grade astrocytomas nant gliomas from male patients banding analysis in-
z cytogenetics will help to dicated a loss of the Y in two cases. Using CGH analy-
mosome in the origin and sis the Y chromosome was detected in all six male
gliomas. cases.
0%
-
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We have begun to apply CGH analyses to low
grade astrocytomas to improve the knowledge of pri-
mary changes in glial cells. Furthermore, the study of
recurrent tumors will help to define an order of genetic
events involved in the progression of gliomas.
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